The neurodegenerative disease investment landscape represents one of the largest and most active therapeutic areas in biopharmaceuticals. With an aging global population and no disease-modifying therapies approved for most conditions, the unmet medical need drives substantial investment across Alzheimer's disease, Parkinson's disease, ALS, and other disorders. The convergence of advances in disease biology, biomarker development, and novel therapeutic modalities has created unprecedented investment opportunities in this space.
The global neurodegenerative disease therapeutics market was valued at approximately $35-40 billion in 2024, with projections suggesting growth to $65+ billion by 2032[1]. Alzheimer's disease accounts for the largest share, followed by Parkinson's disease and other dementias. The market growth is driven by several factors:
Alzheimer's disease represents the largest segment of neurodegeneration investment, with major pharmaceutical companies including Biogen, Eisai, Eli Lilly, and Roche having invested billions in clinical development[6]. The field has evolved from symptomatic treatments to disease-modifying therapies targeting amyloid-beta, tau, and emerging targets like APOE and synaptic proteins.
Key investment areas include:
Parkinson's disease investment has grown substantially, with focus on alpha-synuclein targeting therapies, LRRK2 inhibitors, and gene therapies[7]. Companies including AbbVie, Roche, and numerous biotech companies have active development programs.
Key investment themes include:
ALS investment has accelerated following recent approvals and improved understanding of disease biology[8]. Focus includes SOD1 targeting, C9orf72 approaches, and neuroprotection strategies. The approval of tofersen for SOD1-ALS has validated the genetic stratification approach.
Investment in rare neurodegenerative conditions continues to grow, including:
Large pharmaceutical companies maintain robust neurodegeneration pipelines through internal discovery, academic collaborations, and strategic acquisitions. Major players include:
VC investment in neurodegeneration startups has increased significantly[9]. Notable deals include:
NIH funding for neurodegenerative disease research exceeds $3 billion annually[10], with substantial support from foundations including the Alzheimer's Association, Michael J. Fox Foundation for Parkinson's Research, and ALS Association.
Investment has shifted decisively toward disease-modifying therapies that address underlying pathology rather than just symptoms. This represents a fundamental change from the symptomatic treatment paradigm that dominated for decades.
Genetic stratification and biomarker-driven development enable more targeted therapies. Key genetic targets include:
Recognizing the complexity of neurodegenerative diseases, investment in combination approaches targeting multiple pathways simultaneously has grown. Examples include amyloid + tau targeting, or neuroinflammation + protein aggregation.
Prevention trials in pre-symptomatic populations have become a major investment theme, enabled by biomarker screening. The DIAN-TU, A4, and similar studies have established frameworks for secondary prevention trials.
Investment in biomarkers for diagnosis, patient selection, and treatment response monitoring has expanded significantly. Blood-based biomarkers represent a particularly active area of development[11]. The FDA has approved several biomarker-based diagnostic tests, enabling more precise patient selection.
Beyond traditional small molecules and antibodies, investment has expanded into new therapeutic modalities:
| Phase | AD Trials | PD Trials | ALS Trials | FTD Trials |
|---|---|---|---|---|
| Phase 1 | 480 | 337 | 138 | 34 |
| Phase 2 | 636 | 485 | 216 | 46 |
| Phase 3 | 321 | 253 | 71 | 12 |
| Active Total | 1,208 | 1,061 | 434 | 124 |
The neurodegeneration space has seen significant M&A activity:
| Year | Company | Deal | Value |
|---|---|---|---|
| 2020 | Biogen | Eisai partnership (lecanemab) | $1B+ |
| 2021 | Eli Lilly | Avid Radiopharmaceuticals acquisition | $500M |
| 2022 | Roche | Prothelia licensing | $100M+ |
| 2023 | Novartis | Versanis Bio acquisition | $1.9B |
| 2024 | Eli Lilly | Protoqor acquisition | $200M+ |
| 2024 | AbbVie | Cerevel acquisition | $8.7B |
| 2025 | Roche | CarbX acquisition | $500M+ |
Recent market developments continue to show strong interest in neurodegeneration:
Despite significant investment, the neurodegeneration field faces challenges:
The neurodegeneration investment landscape continues to evolve positively. With multiple disease-modifying therapies now approved or in late-stage development, the field has achieved critical milestones that de-risk future investments. Key areas of continued interest include:
Grand View Research. Neurodegenerative Diseases Market Size, Share & Trends Analysis Report. 2024. ↩︎
United Nations. World Population Prospects 2022. 2022. ↩︎
Alzheimer's Association. Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia. 2024. ↩︎
van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023. ↩︎
Hansson O. Biomarkers for Alzheimer's Disease in Clinical Practice. Nature Reviews Neurology. 2024. ↩︎
Cummings J, et al. Alzheimer's Disease Drug Development Pipeline: 2024. Alzheimer's & Dementia. 2024. ↩︎
Tolosa E, et al. Therapeutic Advances in Parkinson's Disease. Nature Reviews Disease Primers. 2024. ↩︎
Hardiman O, et al. Amyotrophic Lateral Sclerosis. Nature Reviews Disease Primers. 2017. ↩︎
Evaluate Pharma. Venture Capital Investment in CNS Disorders 2023 Report. 2023. ↩︎
NIH. Estimates of Funding for Various Research, Condition, and Disease Categories. 2024. ↩︎
Blennow K, Zetterberg H. Biomarkers for Alzheimer's Disease: Current Status and Future Directions. Nature Reviews Neurology. 2024. ↩︎
Alzheimer's Association. $100 Million Increase for Alzheimer's and Dementia Research Signed into Law. 2026. ↩︎